Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CDXS Stock Summary
Top 10 Correlated ETFs
CDXS
In the News
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
WIX Set to Report Q4 Earnings: Here's What You Should Know
WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.
Codexis, Inc. (CDXS) Q3 2023 Earnings Call Transcript
Codexis, Inc. (CDXS) Q3 2023 Earnings Call Transcript
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in Amsterdam, Netherlands and virtually October 30-November 1, 2023.
Codexis to Report Third Quarter 2023 Financial Results on November 2
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
Checking Out Codexis
Codexis, Inc. is undergoing a significant restructuring to reduce costs, refocus its developmental efforts and streamline its organization. The company's ECO platform to provide enzymes for RNA therapeutics shows some potential, but the company's cash burn rate remains concerning. Insider purchases and consolidation of operations may indicate a turnaround, but previous insider selling this year raises concerns about management's commitment.
The Next Nvidia: 3 AI Stocks That Could Break New Records
With artificial intelligence protocols requiring a ridiculous amount of computing capacity, the demand surge for graphics processing units (GPUs) naturally boosted Nvidia (NASDAQ: NVDA ) but it also leaves the million-dollar question: what investment will be the next Nvidia? To be sure, no one's questioning the long-term viability of NVDA.
CDXS Financial details
CDXS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.21 | 1.16 | 1.62 | 2.12 | 1.03 | |
Net income per share | -0.21 | -0.4 | -0.33 | -0.51 | -1.12 | |
Operating cash flow per share | -0.22 | -0.28 | -0.22 | 0.17 | -0.77 | |
Free cash flow per share | -0.29 | -0.34 | -0.44 | 0.05 | -0.84 | |
Cash per share | 1.6 | 2.53 | 1.81 | 1.74 | 0.96 | |
Book value per share | 1.87 | 2.87 | 2.55 | 2.22 | 1.27 | |
Tangible book value per share | 1.81 | 2.81 | 2.5 | 2.17 | 1.24 | |
Share holders equity per share | 1.87 | 2.87 | 2.55 | 2.22 | 1.27 | |
Interest debt per share | 0.46 | 0.42 | 0.74 | 0.69 | 0.33 | |
Market cap | 903.83M | 1.3B | 2.02B | 304.5M | 207.8M | |
Enterprise value | 839.45M | 1.17B | 1.95B | 234.16M | 164.53M | |
P/E ratio | -75.73 | -53.97 | -94.88 | -9.06 | -2.73 | |
Price to sales ratio | 13.2 | 18.76 | 19.27 | 2.2 | 2.96 | |
POCF ratio | -71.96 | -78.71 | -141.52 | 26.99 | -3.95 | |
PFCF ratio | -55.48 | -64.11 | -71.86 | 102.29 | -3.64 | |
P/B Ratio | 8.57 | 7.62 | 12.28 | 2.1 | 2.4 | |
PTB ratio | 8.57 | 7.62 | 12.28 | 2.1 | 2.4 | |
EV to sales | 12.26 | 16.97 | 18.61 | 1.69 | 2.35 | |
Enterprise value over EBITDA | -66.89 | -48.98 | -85.91 | -8.2 | -3.67 | |
EV to operating cash flow | -66.84 | -71.17 | -136.67 | 20.75 | -3.13 | |
EV to free cash flow | -51.53 | -57.97 | -69.4 | 78.66 | -2.88 | |
Earnings yield | -0.01 | -0.02 | -0.01 | -0.11 | -0.37 | |
Free cash flow yield | -0.02 | -0.02 | -0.01 | 0.01 | -0.27 | |
Debt to equity | 0.25 | 0.15 | 0.29 | 0.3 | 0.26 | |
Debt to assets | 0.18 | 0.11 | 0.19 | 0.17 | 0.16 | |
Net debt to EBITDA | 5.13 | 5.19 | 3.05 | 2.46 | 0.96 | |
Current ratio | 7.42 | 7.38 | 4.85 | 3.32 | 2.61 | |
Interest coverage | 0 | 0 | 0 | -22.01 | 0 | |
Income quality | 1.05 | 0.69 | 0.67 | -0.34 | 0.69 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.24 | -0.05 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.45 | 0.5 | 0.47 | 0.37 | 0 | |
Research and developement to revenue | 0.49 | 0.64 | 0.53 | 0.58 | 0.84 | |
Intangibles to total assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | |
Capex to operating cash flow | 0.3 | 0.23 | 0.97 | -0.74 | 0.08 | |
Capex to revenue | -0.05 | -0.05 | -0.13 | -0.06 | -0.06 | |
Capex to depreciation | -0.82 | -0.82 | -2.33 | -0.81 | -0.45 | |
Stock based compensation to revenue | 0.1 | 0.11 | 0.11 | 0.1 | 0.14 | |
Graham number | 2.98 | 5.11 | 4.34 | 5.06 | 5.66 | |
ROIC | -0.08 | -0.11 | -0.09 | -0.14 | -0.45 | |
Return on tangible assets | -0.08 | -0.11 | -0.09 | -0.14 | -0.57 | |
Graham Net | 1.1 | 2.04 | 0.99 | 0.61 | 0.47 | |
Working capital | 98.82M | 159.44M | 128.52M | 113.83M | 57.64M | |
Tangible asset value | 102.28M | 166.86M | 161.15M | 141.56M | 84.15M | |
Net current asset value | 70.65M | 132.88M | 79.9M | 57.3M | 43.52M | |
Invested capital | 0.25 | 0.15 | 0.29 | 0.3 | 0.26 | |
Average receivables | 16.33M | 24.72M | 33.47M | 39.26M | 30.4M | |
Average payables | 2.84M | 2.8M | 2.98M | 3.12M | 4.6M | |
Average inventory | 480K | 667.5K | 1.06M | 1.59M | 2.36M | |
Days sales outstanding | 107.46 | 154.8 | 131.19 | 107.65 | 103.7 | |
Days payables outstanding | 61.2 | 78.89 | 49.22 | 31.15 | 118.44 | |
Days of inventory on hand | 8.66 | 25.6 | 19.06 | 19.47 | 53.47 | |
Receivables turnover | 3.4 | 2.36 | 2.78 | 3.39 | 3.52 | |
Payables turnover | 5.96 | 4.63 | 7.42 | 11.72 | 3.08 | |
Inventory turnover | 42.13 | 14.26 | 19.15 | 18.74 | 6.83 | |
ROE | -0.11 | -0.14 | -0.13 | -0.23 | -0.88 | |
Capex per share | -0.07 | -0.06 | -0.21 | -0.13 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.47 | 0.2 | 0.32 | 0.13 | 0.38 | |
Net income per share | -0.19 | -0.34 | -0.17 | -0.5 | -0.1 | |
Operating cash flow per share | 0.08 | -0.14 | -0.24 | -0.23 | -0.16 | |
Free cash flow per share | 0.08 | -0.18 | -0.26 | -0.24 | -0.15 | |
Cash per share | 1.75 | 1.56 | 1.36 | 1.07 | 0.94 | |
Book value per share | 2.23 | 1.91 | 1.84 | 1.32 | 1.25 | |
Tangible book value per share | 2.18 | 1.86 | 1.79 | 1.28 | 1.21 | |
Share holders equity per share | 2.23 | 1.91 | 1.84 | 1.32 | 1.25 | |
Interest debt per share | 0.68 | 0.63 | 0.61 | 0.29 | 0.32 | |
Market cap | 303.07M | 272.95M | 189.2M | 131.29M | 211.98M | |
Enterprise value | 232.72M | 212.46M | 138.12M | 76.69M | 168.7M | |
P/E ratio | -6.01 | -3.02 | -4.1 | -0.94 | -7.37 | |
Price to sales ratio | 9.98 | 21.03 | 8.87 | 14.15 | 7.98 | |
POCF ratio | 61.64 | -29.63 | -11.76 | -8.05 | -19.21 | |
PFCF ratio | 61.23 | -23.23 | -10.71 | -7.73 | -19.89 | |
P/B Ratio | 2.09 | 2.17 | 1.52 | 1.43 | 2.45 | |
PTB ratio | 2.09 | 2.17 | 1.52 | 1.43 | 2.45 | |
EV to sales | 7.66 | 16.37 | 6.48 | 8.27 | 6.35 | |
Enterprise value over EBITDA | -33.64 | -9.03 | -14.19 | -13.2 | 74.81 | |
EV to operating cash flow | 47.33 | -23.06 | -8.59 | -4.7 | -15.29 | |
EV to free cash flow | 47.01 | -18.08 | -7.82 | -4.52 | -15.83 | |
Earnings yield | -0.04 | -0.08 | -0.06 | -0.27 | -0.03 | |
Free cash flow yield | 0.02 | -0.04 | -0.09 | -0.13 | -0.05 | |
Debt to equity | 0.3 | 0.34 | 0.33 | 0.22 | 0.26 | |
Debt to assets | 0.17 | 0.19 | 0.2 | 0.13 | 0.16 | |
Net debt to EBITDA | 10.17 | 2.57 | 5.25 | 9.39 | -19.19 | |
Current ratio | 3.32 | 3.39 | 3.36 | 2.68 | 2.61 | |
Interest coverage | -12.25 | 22.24 | 0 | 0 | 0 | |
Income quality | -0.39 | 0.41 | 1.4 | 0.47 | 1.53 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.4 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.65 | 1.28 | 0.81 | 1.47 | 0.42 | |
Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
Capex to operating cash flow | 0.01 | 0.28 | 0.1 | 0.04 | -0.03 | |
Capex to revenue | 0 | -0.2 | -0.07 | -0.07 | 0.01 | |
Capex to depreciation | 0.01 | -0.94 | -0.58 | -0.27 | 0.19 | |
Stock based compensation to revenue | 0.1 | 0.22 | 0.13 | 0.25 | 0.08 | |
Graham number | 3.12 | 3.84 | 2.65 | 3.86 | 1.7 | |
ROIC | -0.04 | -0.11 | -0.06 | -0.24 | 0 | |
Return on tangible assets | -0.05 | -0.11 | -0.06 | -0.23 | -0.05 | |
Graham Net | 0.62 | 0.41 | 0.4 | 0.39 | 0.46 | |
Working capital | 113.83M | 91.64M | 84.31M | 64.6M | 57.64M | |
Tangible asset value | 141.56M | 122.78M | 120.89M | 89.04M | 84.15M | |
Net current asset value | 57.3M | 37.9M | 37.41M | 40.07M | 43.52M | |
Invested capital | 0.3 | 0.34 | 0.33 | 0.22 | 0.26 | |
Average receivables | 35.32M | 30.45M | 20.81M | 20.35M | 19.51M | |
Average payables | 2.93M | 3.87M | 4.27M | 3.57M | 4.52M | |
Average inventory | 1.83M | 2.01M | 2.02M | 2.18M | 2.5M | |
Days sales outstanding | 121.11 | 138.77 | 91.22 | 185.23 | 67.52 | |
Days payables outstanding | 34.55 | 89.46 | 114.47 | 123.98 | 131.25 | |
Days of inventory on hand | 21.6 | 39.73 | 58.11 | 92.24 | 59.26 | |
Receivables turnover | 0.74 | 0.65 | 0.99 | 0.49 | 1.33 | |
Payables turnover | 2.61 | 1.01 | 0.79 | 0.73 | 0.69 | |
Inventory turnover | 4.17 | 2.27 | 1.55 | 0.98 | 1.52 | |
ROE | -0.09 | -0.18 | -0.09 | -0.38 | -0.08 | |
Capex per share | 0 | -0.04 | -0.02 | -0.01 | 0.01 |
CDXS Frequently Asked Questions
What is Codexis, Inc. stock symbol ?
Codexis, Inc. is a US stock , located in Redwood city of Ca and trading under the symbol CDXS
What is Codexis, Inc. stock quote today ?
Codexis, Inc. stock price is $3.5999 today.
Is Codexis, Inc. stock public?
Yes, Codexis, Inc. is a publicly traded company.